IMPORTANT INFORMATION

  • CFTR.info is an online educational resource on the genetics of cystic fibrosis (CF) and the role of CF transmembrane conductance regulator (CFTR) in normal human physiology as well as in CF.
  • The information contained herein is intended for healthcare professionals working within the European Union (EU).
  • The content of this website has been developed independently by a group of CF healthcare professionals and is for general information purposes only.
  • All of the information about CFTR and CFTR modulators has been obtained from referenced sources and is in the public domain.
  • This website is not intended to promote or advocate a particular course of treatment or any specific drug, whether licensed or unlicensed, nor is it intended to imply or suggest that any drug be used for any purpose other than that which for which it is licensed in the EU.

ABBREVIATED TERMS & CONDITIONS

  • While we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information and related graphics, or products and treatments, contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
  • In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from, or in connection with, the use of this website.
  • Through this website you are able to link to other websites which are not under our control. We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
  • Every effort is made to keep the website up and running smoothly. However, we take no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

Please see the full Terms & Conditions before using this website.

 

I have read and understood the above

Drug & research development » Clinical trials » NCT02141464

Energy Balance and Weight Gain With Ivacaftor Treatment

Official title: Energy Balance and Weight Gain With Ivacaftor Treatment of CFTR Gating Mutations

Clinical Trials gov number: NCT02141464

Click on the tabs to move through the sequence.

Purpose: To determine the mechanism(s) for weight gain in participants whom ivacaftor treatment was initiated based on clinical indications by CF Care Team. Assess energy expenditure, weight gain, body composition, and lung function in 24 CF patients aged ≥6 years with a gating mutation before treatment and after three months treatment with ivacaftor.

Phase: NA

Type: Observational, prospective, cohort

Study sponsor: Children’s Hospital of Philadelphia

  • Cystic fibrosis with one or two CFTR gating mutations
  • A clinical decision has been made for the subject to start ivacaftor treatment
  • In usual state of good health
  • Family and subject commitment to the 3-month study protocol with two, 3-4 day visits to CHOP

Intervention
Ivacaftor

Geographical Location
United States

Number of Participants
≤50 (≥6 years)

Primary Endpoint

Significant reduction in resting energy expenditure over 3 months

Secondary Endpoint

Not provided

Click on the tabs to move through the sequence.

Not provided

View Trial Results